
Opinion|Videos|June 11, 2024
ADRIATIC: Durvalumab as Consolidation Treatment for Limited-Stage SCLC
Joshua K. Sabari, MD, and the Oncology Brothers discuss recent findings from the ADRIATIC study focused on durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Lung Cancer News Roundup: June 2026
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
New Research Links Food Access to Breast Cancer Biology
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5










































